Information about Trizivir (Abacavir / Lamivudine / Zidovudine)
Trizivir contains Abacavir, Lamivudine, and Zidovudine, which are all nucleoside reverse transcriptase inhibitors (NRTIs). These drugs block reverse transcriptase, an enzyme HIV needs to replicate, thus preventing the virus from spreading within the body. This combination therapy helps reduce the viral load and increase CD4+ cell counts, which are crucial for immune defense.
Product Highlights
- Trizivir is indicated for the treatment of HIV-1 infection in adults and children over a certain age and weight. It is used as part of a comprehensive HIV treatment regimen.
- It is typically prescribed for patients who are antiretroviral-naive (have never been treated for HIV) or those who require a combination therapy.
Key Ingredients
- Abacavir
- Lamivudine
- Zidovudine
Key Benefits
- Trizivir is effective at reducing HIV viral load and increasing CD4+ cell counts, helping to slow the progression of the disease.
- By combining three medications into one tablet, it simplifies the treatment regimen and may improve patient adherence.
- The combination of three NRTIs helps to minimize the development of resistance to the drugs, compared to single-agent therapies.
- Trizivir is typically taken twice daily, which is more convenient than some other regimens that require more frequent dosing.
Direction of Use
- The typical dose for adults is one tablet twice daily. Dosage for children depends on age and body weight.
- Trizivir should be taken with or without food, as food does not significantly affect the absorption of the medication.
- If you forget a dose, take it as soon as you recall, unless it's almost time for your next dose. In that situation, skip the missed dose and continue with your regular schedule—do not take two doses together.
Safety Concerns
- Abacavir can cause a severe, potentially life-threatening allergic reaction. Patients should be screened for the HLA-B*5701 gene before starting the medication, as those who are positive for this gene are at higher risk.
- Zidovudine has been linked to bone marrow suppression, which can result in low blood cell counts, leading to anemia, neutropenia, or thrombocytopenia. Regular blood tests are required to monitor this.
- Both Abacavir and Zidovudine have been associated with liver problems, including hepatitis and lactic acidosis, so regular monitoring of liver function is necessary.
- Some patients may experience nausea, vomiting, or diarrhea, especially when starting the medication.
- Long-term use of NRTIs, including Zidovudine and Lamivudine, can cause changes in fat distribution (lipodystrophy), leading to fat accumulation in certain areas of the body.
Avoid Trizivir (Abacavir / Lamivudine / Zidovudine) If
- You are allergic to Abacavir, Lamivudine, Zidovudine, or any other ingredient in Trizivir.
- You are HLA-B*5701 positive (testing is recommended before starting Abacavir).
- You have a history of severe liver disease or hepatic impairment (especially with Zidovudine).
- You have severe bone marrow suppression (low red blood cells, white blood cells, or platelets).
- You are pregnant or breastfeeding, unless advised otherwise by your healthcare provider. Zidovudine has been used in pregnancy for HIV treatment but requires careful monitoring.
- You have a history of lactic acidosis, as NRTIs like Abacavir and Zidovudine are associated with this condition.
- You are taking other medications that can interact with the components of Trizivir, especially other antivirals or medications that affect liver function.
